<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Come Meet A Black Person | Mcclure Conner | Activity</title>
	<link>https://comemeetablackperson.com/members/crayondish9/activity/</link>
	<atom:link href="https://comemeetablackperson.com/members/crayondish9/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Mcclure Conner.</description>
	<lastBuildDate>Wed, 22 Jul 2026 19:47:47 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">1dc05b046c9ca3ea849e3e750c36787f</guid>
				<title>Mcclure Conner posted an update: Nevertheless, the authors are confident that some vaccine [&#133;]</title>
				<link>https://comemeetablackperson.com/activity/p/4455/</link>
				<pubDate>Mon, 30 Oct 2023 07:33:41 -0400</pubDate>

									<content:encoded><![CDATA[<p>Nevertheless, the authors are confident that some vaccine candidates will meet these criteria.BNT162b2 dose in patients with plasma cell disorders.morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody response to COVID-19 vaccination.&hellip;<span class="activity-read-more" id="activity-read-more-4455"><a href="https://comemeetablackperson.com/activity/p/4455/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cd3f5267ca88b91cddd5fd14a2cc9998</guid>
				<title>Mcclure Conner became a registered member</title>
				<link>https://comemeetablackperson.com/activity/p/4415/</link>
				<pubDate>Mon, 30 Oct 2023 06:46:11 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>